Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:ANIP

ANI Pharmaceuticals Q3 2026 Earnings Date & Estimates

ANI Pharmaceuticals logo
$73.89 +1.91 (+2.65%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$73.83 -0.06 (-0.08%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ANI Pharmaceuticals is scheduled to report Q3 2026 earnings on Friday, November 6, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from ANI Pharmaceuticals in Q3 2026

ANI Pharmaceuticals is expected to post earnings of $2.17 per share on revenue of $280.25 million. In the same quarter a year earlier ANI Pharmaceuticals reported $2.04 per share on revenue of $227.81 million. ANI Pharmaceuticals last reported on August 7, 2026, posting $2.21 per share and beating the $2.04 consensus estimate. ANI Pharmaceuticals has beaten the consensus EPS estimate in 8 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$2.17
Expected Revenue
$280.25 million
Prior-Year EPS
$2.04
Prior-Year Revenue
$227.81 million
Expected EPS Growth
+6.4%
Expected Revenue Growth
+23.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$2.21 (Beat by +$0.17)
Last Quarter Revenue
$266.04 million
EPS Beat Rate
8 of last 8 quarters

Prepare for the Q3 2026 Call

ANI Pharmaceuticals Q3 2026 Earnings FAQ

ANI Pharmaceuticals (NASDAQ:ANIP) is scheduled to report Q3 2026 earnings on Friday, November 6, 2026, before market opens.

ANI Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect ANI Pharmaceuticals to post earnings of $2.17 per share for Q3 2026.

The consensus revenue estimate for ANI Pharmaceuticals is $280.25 million for Q3 2026.

ANI Pharmaceuticals Earnings Headlines

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Has Average Target Price of $98.00
October 8 at 2:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31097950
Did FDA Approval of Generic Everolimus Suspension Just Shift ANI Pharmaceuticals' (ANIP) Investment Narrative?
October 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/did-fda-approval-generic-everolimus-221336723.html
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
 |  Porter & Company (Ad)
Comparing Talphera (NASDAQ:TLPH) & ANI Pharmaceuticals (NASDAQ:ANIP)
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31091522
Comparing Sunshine Biopharma (NASDAQ:SBFM) and ANI Pharmaceuticals (NASDAQ:ANIP)
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085994
ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting
September 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/30/3371724/0/en/ani-pharmaceuticals-announces-new-fluocinolone-acetonide-intravitreal-implant-data-to-be-presented-at-the-american-academy-of-ophthalmology-2026-annual-meeting.html
See More ANI Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ANI Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ANI Pharmaceuticals and other key companies, straight to your email.

About ANI Pharmaceuticals

ANI Pharmaceuticals (NASDAQ:ANIP) is a specialty pharmaceutical company that develops, manufactures and commercializes branded and generic prescription medicines. The company focuses on products with complex formulations, difficult-to-manufacture dosage forms and limited competition, serving therapeutic areas that include rare diseases, ophthalmology, endocrinology, central nervous system conditions and other specialty markets.

ANI’s portfolio includes Cortrophin Gel (repository corticotropin injection), a specialty therapy used for certain inflammatory and autoimmune conditions, as well as a range of established brand and generic products. Through its acquisition of Alimera Sciences, ANI expanded its ophthalmology business with products such as ILUVIEN and YUTIQ, which are used in the treatment of retinal diseases. The company also operates pharmaceutical manufacturing and development capabilities in the United States.

ANI primarily serves the U.S. prescription pharmaceutical market through commercial, specialty and institutional channels. The company’s history includes the expansion of its product portfolio through acquisitions and the development of higher-value specialty medicines alongside its established generic and branded products. Nikhil Lalwani serves as ANI Pharmaceuticals’ president and chief executive officer.

View ANI Pharmaceuticals Profile
Earnings Tools